The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.
Your immune system harbors a lifetime's worth of information about threats it's encountered—a biological Rolodex of baddies.
MarketBeat on MSN4d
Regeneron: Is It the Perfect Biotech Stock for Value and Growth?CompanyOverview|NASDAQ:REGN] Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major ...
The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Regeneron is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a three-part study with ...
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid <li /> If approved, Dupixent would be the ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 </stron ...
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top pick for long-term investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback